Miryoung Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Miryoung Song has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Daejin Lim
Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea
4 shared publications- Daejin Lim
Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon, Republic of Korea
4 shared publications Heejoon Myung
Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies, Yongin, Republic of Korea
3 shared publicationsJeonghyun Lim
Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies, Yongin, Republic of Korea
3 shared publicationsDogeun Lee
Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon, Republic of Korea
2 shared publications- Hyon E. Choy
Departments of Microbiology & Immunology, Basic Medical Research Building, Chonnam National University Medical College, Hwasun, South Korea
2 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Springer Nature in Microbial Cell Factories
- Vol. 25  (1)
Engineering an E. coli Nissle 1917 platform for the co-delivery of iNTS antigens and a genetically optimized flagellin adjuvant
- 18 August 2026
- Published by Springer Nature in Microbial Cell Factories
- Vol. 25  (1)
Open AccessEngineering an E. coli Nissle 1917 platform for the co-delivery of iNTS antigens and a genetically optimized flagellin adjuvant
- Open Access
- 31 July 2026
- Published by Springer Nature in Journal of Biological Engineering
- Vol. 20  (1)
aspA promoter as a tumor microenvironment-responsive autoswitch for anticancer agent expression in Escherichia coli
Bacterial cancer therapy has emerged as a promising strategy for the local delivery of anticancer agents to solid tumors because bacteria preferentially colonize the tumor microenvironment (TME). However, strategies for exploiting metabolic features of the TME to achieve tumor-selective expression of anticancer agents remain limited. Here, we present a tumor-responsive gene expression system in Escherichia coli for tumor-selective expression of the recombinant immunotoxin psp-TGFa-PE38 (TP), exploiting its intrinsic ability to sense metabolic cues in the TME. To identify such TME-associated metabolic cues, we examined tumor metabolites in CT26 tumor-bearing mice and confirmed that tumors contained > 3-fold lower glucose and > 5-fold higher fumarate levels than those in the liver. In response to this nutrient heterogeneity, E. coli upregulated genes involved in fumarate respiration, including frdA , dctA , dcuB , and aspA , in the DcuSR regulon. aspA was most upregulated (65-fold) in tumors, which is indicative of the strongest activity of its promoter in the TME. We used the aspA promoter (P aspA ) as a tumor-specific switch to control TP expression, targeting secreted functional TP and inducing cytotoxicity in vitro. TP was specifically expressed by P aspA in tumors, reducing the tumor size by 2.8-fold and extending survival by 35 days in vivo. Overall, these results suggest that the potential of P aspA as a tumor-specific expression system.
- 31 July 2026
- Published by Springer Nature in Journal of Biological Engineering
- Vol. 20  (1)
Open AccessaspA promoter as a tumor microenvironment-responsive autoswitch for anticancer agent expression in Escherichia coli
Bacterial cancer therapy has emerged as a promising strategy for the local delivery of anticancer agents to solid tumors because bacteria preferentially colonize the tumor microenvironment (TME). However, strategies for exploiting metabolic features of the TME to achieve tumor-selective expression of anticancer agents remain limited. Here, we present a tumor-responsive gene expression system in Escherichia coli for tumor-selective expression of the recombinant immunotoxin psp-TGFa-PE38 (TP), exploiting its intrinsic ability to sense metabolic cues in the TME. To identify such TME-associated metabolic cues, we examined tumor metabolites in CT26 tumor-bearing mice and confirmed that tumors contained > 3-fold lower glucose and > 5-fold higher fumarate levels than those in the liver. In response to this nutrient heterogeneity, E. coli upregulated genes involved in fumarate respiration, including frdA , dctA , dcuB , and aspA , in the DcuSR regulon. aspA was most upregulated (65-fold) in tumors, which is indicative of the strongest activity of its promoter in the TME. We used the aspA promoter (P aspA ) as a tumor-specific switch to control TP expression, targeting secreted functional TP and inducing cytotoxicity in vitro. TP was specifically expressed by P aspA in tumors, reducing the tumor size by 2.8-fold and extending survival by 35 days in vivo. Overall, these results suggest that the potential of P aspA as a tumor-specific expression system.
- 17 April 2026
- Published by Springer Nature in Oncogene
- Vol. 45  (21) , 2046-2057
Antitumor immunotoxin expression is enhanced by Escherichia coli csrB-promoter activity
In bacterial oncotherapy, tumor-targeting bacteria deliver cytotoxins that induce cancer-cell apoptosis, requiring exogenous cues to induce such cytotoxins. We mined the part of the Escherichia coli genome regulating immunotoxin (anticancer protein) to maximize tumor-specific activity. E. coli was introduced into a mouse tumor model, and RNA-seq analysis was performed. csrB, encoding small regulatory RNA, was highly upregulated in tumors. Genes controlled by csrB participate in acetate metabolism, enriched in the tumor microenvironment. qPCR of in vitro bacterial culture revealed that csrB expression depended on acetate levels. The csrB-promoter regulated acetate-controlled expression of β-galactosidase. For E. coli-mediated oncotherapy, we therefore selected the csrB promoter to regulate a recombinant form of immunotoxin, psp-TGFα–PE38, comprising TGFα, Pseudomonas exotoxin A, with a secretion tag (psp). Under csrB-promoter control, TP was notably expressed when acetate was present. Tumor-cell viability was dramatically reduced following treatment with the TP-containing bacterial-culture supernatant. TP was continuously present in the tumors of CT26-tumor-bearing mice administered TP-expressing E. coli. When exogenous stimuli were absent and TP was expressed by E. coli, tumor growth was substantially retarded, and the survival period increased. Tumor-colonizing bacteria thus offer promise in sensing tumor conditions and altering antitumor protein expression, potentially improving outcomes.
- 17 April 2026
- Published by Springer Nature in Oncogene
- Vol. 45  (21) , 2046-2057
Antitumor immunotoxin expression is enhanced by Escherichia coli csrB-promoter activity
In bacterial oncotherapy, tumor-targeting bacteria deliver cytotoxins that induce cancer-cell apoptosis, requiring exogenous cues to induce such cytotoxins. We mined the part of the Escherichia coli genome regulating immunotoxin (anticancer protein) to maximize tumor-specific activity. E. coli was introduced into a mouse tumor model, and RNA-seq analysis was performed. csrB, encoding small regulatory RNA, was highly upregulated in tumors. Genes controlled by csrB participate in acetate metabolism, enriched in the tumor microenvironment. qPCR of in vitro bacterial culture revealed that csrB expression depended on acetate levels. The csrB-promoter regulated acetate-controlled expression of β-galactosidase. For E. coli-mediated oncotherapy, we therefore selected the csrB promoter to regulate a recombinant form of immunotoxin, psp-TGFα–PE38, comprising TGFα, Pseudomonas exotoxin A, with a secretion tag (psp). Under csrB-promoter control, TP was notably expressed when acetate was present. Tumor-cell viability was dramatically reduced following treatment with the TP-containing bacterial-culture supernatant. TP was continuously present in the tumors of CT26-tumor-bearing mice administered TP-expressing E. coli. When exogenous stimuli were absent and TP was expressed by E. coli, tumor growth was substantially retarded, and the survival period increased. Tumor-colonizing bacteria thus offer promise in sensing tumor conditions and altering antitumor protein expression, potentially improving outcomes.
- Open Access
- 19 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16  (1)
Tumor-specific cytokine therapy mediated by engineered Salmonella with a synthetic protein delivery system
Cytokine treatment provides clinical benefits by stimulating the patient’s immune system to attack cancer cells. However, its effectiveness as a monotherapy is limited because of its systemic toxicity and short in vivo half-life. To address these limitations, we assessed the therapeutic impact of delivering cytokines specifically to tumors using tumor-targeting bacteria. A Salmonella strain was engineered to minimize its pathogenic traits by deleting key elements (Salmonella pathogenicity islands-1 and -2) responsible for invasion and replication within the mammalian host, generating the ΔSPI-1ΔSPI-2 strain. A plasmid encoding a synthetic type 3 secretion system (SynT3SS V3.0) was introduced into this strain using a previously reported genetic system after reorganizing the gene clusters and placed under control of the Ptet promoter. Finally, the anticancer cytokine Neoleukin-2/15 (Neo-2/15) was introduced into the strain via a separate plasmid. This plasmid encoded an N-terminal secretion signal from SptP (SptP167) and was driven by the constitutive promoter PJ23110. Upon inducing SynT3SS V3.0 using doxycycline, the recombinant protein SptP167::Neo-2/15 was secreted into the bacterial culture supernatant with a yield of 0.37 ± 0.07 mg/L. Starved cytotoxic T lymphocytes treated with the culture supernatant containing SptP167::Neo-2/15 proliferated, as observed with hIL-2, purified Neo-2/15, or purified SptP167::Neo-2/15 treatment. Administering Salmonella ΔSPI-1ΔSPI-2 strains carrying plasmids encoding SynT3SS V3.0 and SptP167::Neo-2/15 caused tumor regression and lifespan extension in CT26 tumor-bearing mice. Engineered bacteria represent a promising new modality for cancer therapy by combining the targeted delivery of therapeutic cytokines with the synergistic immunostimulatory effects of bacterial intrinsic factors. Furthermore, this strategy could be adapted for other protein-based payloads, potentially enabling the tumor-specific delivery of a diverse range of therapeutic agents.
- 19 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16  (1)
Open AccessTumor-specific cytokine therapy mediated by engineered Salmonella with a synthetic protein delivery system
Cytokine treatment provides clinical benefits by stimulating the patient’s immune system to attack cancer cells. However, its effectiveness as a monotherapy is limited because of its systemic toxicity and short in vivo half-life. To address these limitations, we assessed the therapeutic impact of delivering cytokines specifically to tumors using tumor-targeting bacteria. A Salmonella strain was engineered to minimize its pathogenic traits by deleting key elements (Salmonella pathogenicity islands-1 and -2) responsible for invasion and replication within the mammalian host, generating the ΔSPI-1ΔSPI-2 strain. A plasmid encoding a synthetic type 3 secretion system (SynT3SS V3.0) was introduced into this strain using a previously reported genetic system after reorganizing the gene clusters and placed under control of the Ptet promoter. Finally, the anticancer cytokine Neoleukin-2/15 (Neo-2/15) was introduced into the strain via a separate plasmid. This plasmid encoded an N-terminal secretion signal from SptP (SptP167) and was driven by the constitutive promoter PJ23110. Upon inducing SynT3SS V3.0 using doxycycline, the recombinant protein SptP167::Neo-2/15 was secreted into the bacterial culture supernatant with a yield of 0.37 ± 0.07 mg/L. Starved cytotoxic T lymphocytes treated with the culture supernatant containing SptP167::Neo-2/15 proliferated, as observed with hIL-2, purified Neo-2/15, or purified SptP167::Neo-2/15 treatment. Administering Salmonella ΔSPI-1ΔSPI-2 strains carrying plasmids encoding SynT3SS V3.0 and SptP167::Neo-2/15 caused tumor regression and lifespan extension in CT26 tumor-bearing mice. Engineered bacteria represent a promising new modality for cancer therapy by combining the targeted delivery of therapeutic cytokines with the synergistic immunostimulatory effects of bacterial intrinsic factors. Furthermore, this strategy could be adapted for other protein-based payloads, potentially enabling the tumor-specific delivery of a diverse range of therapeutic agents.
- Open Access
- 10 July 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14  (12) , 5479-5492
Controlling tumor progression and recurrence in mice through combined treatment with a PD-L1 inhibitor and a designer Salmonella strain that delivers GM-CSF
- 10 July 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14  (12) , 5479-5492
Open AccessControlling tumor progression and recurrence in mice through combined treatment with a PD-L1 inhibitor and a designer Salmonella strain that delivers GM-CSF
- Open Access
- 15 April 2024
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 31  (1) , 1-9
Antimicrobial peptide thanatin fused endolysin PA90 (Tha-PA90) for the control of Acinetobacter baumannii infection in mouse model
Background: This study addresses the urgent need for infection control agents driven by the rise of drug-resistant pathogens such as Acinetobacter baumannii. Our primary aim was to develop and assess a novel endolysin, Tha-PA90, designed to combat these challenges. Methods: Tha-PA90 incorporates an antimicrobial peptide (AMP) called thanatin at its N-terminus, enhancing bacterial outer membrane permeability and reducing host immune responses. PA90 was selected as the endolysin component. The antibacterial activity of the purified Tha-PA90 was evaluated using an in vitro colony-forming unit (CFU) reduction assay and a membrane permeability test. A549 cells were utilized to measure the penetration into the cytosol and the cytotoxicity of Tha-PA90. Finally, infection control was monitored in A. baumannii infected mice following the intraperitoneal administration of Tha-PA90. Results: Tha-PA90 demonstrated remarkable in vitro efficacy, completely eradicating A. baumannii strains, even drug-resistant variants, at a low concentration of 0.5 μM. Notably, it outperformed thanatin, achieving only a < 3-log reduction at 4 μM. Tha-PA90 exhibited 2–3 times higher membrane permeability than a PA90 and thanatin mixture or PA90 alone. Tha-PA90 was found within A549 cells' cytosol with no discernible cytotoxic effects. Furthermore, Tha-PA90 administration extended the lifespan of A. baumannii-infected mice, reducing bacterial loads in major organs by up to 3 logs. Additionally, it decreased proinflammatory cytokine levels (TNF-α and IL-6), reducing the risk of sepsis from rapid bacterial lysis. Our findings indicate that Tha-PA90 is a promising solution for combating drug-resistant A. baumannii. Its enhanced efficacy, low cytotoxicity, and reduction of proinflammatory responses render it a potential candidate for infection control. Conclusions: This study underscores the significance of engineered endolysins in addressing the pressing challenge of drug-resistant pathogens and offers insights into improved infection management strategies.
- 15 April 2024
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 31  (1) , 1-9
Open AccessAntimicrobial peptide thanatin fused endolysin PA90 (Tha-PA90) for the control of Acinetobacter baumannii infection in mouse model
Background: This study addresses the urgent need for infection control agents driven by the rise of drug-resistant pathogens such as Acinetobacter baumannii. Our primary aim was to develop and assess a novel endolysin, Tha-PA90, designed to combat these challenges. Methods: Tha-PA90 incorporates an antimicrobial peptide (AMP) called thanatin at its N-terminus, enhancing bacterial outer membrane permeability and reducing host immune responses. PA90 was selected as the endolysin component. The antibacterial activity of the purified Tha-PA90 was evaluated using an in vitro colony-forming unit (CFU) reduction assay and a membrane permeability test. A549 cells were utilized to measure the penetration into the cytosol and the cytotoxicity of Tha-PA90. Finally, infection control was monitored in A. baumannii infected mice following the intraperitoneal administration of Tha-PA90. Results: Tha-PA90 demonstrated remarkable in vitro efficacy, completely eradicating A. baumannii strains, even drug-resistant variants, at a low concentration of 0.5 μM. Notably, it outperformed thanatin, achieving only a < 3-log reduction at 4 μM. Tha-PA90 exhibited 2–3 times higher membrane permeability than a PA90 and thanatin mixture or PA90 alone. Tha-PA90 was found within A549 cells' cytosol with no discernible cytotoxic effects. Furthermore, Tha-PA90 administration extended the lifespan of A. baumannii-infected mice, reducing bacterial loads in major organs by up to 3 logs. Additionally, it decreased proinflammatory cytokine levels (TNF-α and IL-6), reducing the risk of sepsis from rapid bacterial lysis. Our findings indicate that Tha-PA90 is a promising solution for combating drug-resistant A. baumannii. Its enhanced efficacy, low cytotoxicity, and reduction of proinflammatory responses render it a potential candidate for infection control. Conclusions: This study underscores the significance of engineered endolysins in addressing the pressing challenge of drug-resistant pathogens and offers insights into improved infection management strategies.
- Open Access
Characterization of Three Different Endolysins Effective against Gram-Negative Bacteria
Genes encoding endolysins were identified and cloned from three different Escherichia coli bacteriophages, 10-24(13), PBEC30, and PBEC56. Putative antimicrobial peptide (AMP)-like C-terminal alpha helix structures with amphipathic natures were predicted from the three endolysins. Each gene was cloned and expressed as hexahistidine-tagged forms, and the products were purified and characterized. The purified endolysins exhibited antibacterial activities against a variety of Gram-negative bacteria including Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumonia. Their antibacterial activities were improved by N-terminal fusion with an antimicrobial peptide, cecropin A. Minimum inhibitory concentrations (MIC) were as low as 4 μg/mL, depending on the targeted strain. The endolysins’ enzymatic activities were not affected by changes in pH at ranges from 5 to 10 and were stable at temperatures between 4 and 65 °C. The in vivo efficacies of the three endolysins were also demonstrated using Galleria melonella for infection models.
Open AccessCharacterization of Three Different Endolysins Effective against Gram-Negative Bacteria
Genes encoding endolysins were identified and cloned from three different Escherichia coli bacteriophages, 10-24(13), PBEC30, and PBEC56. Putative antimicrobial peptide (AMP)-like C-terminal alpha helix structures with amphipathic natures were predicted from the three endolysins. Each gene was cloned and expressed as hexahistidine-tagged forms, and the products were purified and characterized. The purified endolysins exhibited antibacterial activities against a variety of Gram-negative bacteria including Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumonia. Their antibacterial activities were improved by N-terminal fusion with an antimicrobial peptide, cecropin A. Minimum inhibitory concentrations (MIC) were as low as 4 μg/mL, depending on the targeted strain. The endolysins’ enzymatic activities were not affected by changes in pH at ranges from 5 to 10 and were stable at temperatures between 4 and 65 °C. The in vivo efficacies of the three endolysins were also demonstrated using Galleria melonella for infection models.
- Open Access
Constitutive Expression of a Cytotoxic Anticancer Protein in Tumor-Colonizing Bacteria
Bacterial cancer therapy is a promising next-generation modality to treat cancer that often uses tumor-colonizing bacteria to deliver cytotoxic anticancer proteins. However, the expression of cytotoxic anticancer proteins in bacteria that accumulate in the nontumoral reticuloendothelial system (RES), mainly the liver and spleen, is considered detrimental. This study examined the fate of the Escherichia coli strain MG1655 and an attenuated strain of Salmonella enterica serovar Gallinarum (S. Gallinarum) with defective ppGpp synthesis after intravenous injection into tumor-bearing mice (~108 colony forming units/animal). Approximately 10% of the injected bacteria were detected initially in the RES, whereas approximately 0.01% were in tumor tissues. The bacteria in the tumor tissue proliferated vigorously to up to 109 colony forming units/g tissue, whereas those in the RES died off. RNA analysis revealed that tumor-associated E. coli activated rrnB operon genes encoding the rRNA building block of ribosome needed most during the exponential stage of growth, whereas those in the RES expressed substantially decreased levels of this gene and were cleared soon presumably by innate immune systems. Based on this finding, we engineered ΔppGpp S. Gallinarum to express constitutively a recombinant immunotoxin comprising TGFα and the Pseudomonas exotoxin A (PE38) using a constitutive exponential phase promoter, the ribosomal RNA promoter rrnB P1. The construct exerted anticancer effects on mice grafted with mouse colon (CT26) or breast (4T1) tumor cells without any notable adverse effects, suggesting that constitutive expression of cytotoxic anticancer protein from rrnB P1 occurred only in tumor tissue.
Open AccessConstitutive Expression of a Cytotoxic Anticancer Protein in Tumor-Colonizing Bacteria
Bacterial cancer therapy is a promising next-generation modality to treat cancer that often uses tumor-colonizing bacteria to deliver cytotoxic anticancer proteins. However, the expression of cytotoxic anticancer proteins in bacteria that accumulate in the nontumoral reticuloendothelial system (RES), mainly the liver and spleen, is considered detrimental. This study examined the fate of the Escherichia coli strain MG1655 and an attenuated strain of Salmonella enterica serovar Gallinarum (S. Gallinarum) with defective ppGpp synthesis after intravenous injection into tumor-bearing mice (~108 colony forming units/animal). Approximately 10% of the injected bacteria were detected initially in the RES, whereas approximately 0.01% were in tumor tissues. The bacteria in the tumor tissue proliferated vigorously to up to 109 colony forming units/g tissue, whereas those in the RES died off. RNA analysis revealed that tumor-associated E. coli activated rrnB operon genes encoding the rRNA building block of ribosome needed most during the exponential stage of growth, whereas those in the RES expressed substantially decreased levels of this gene and were cleared soon presumably by innate immune systems. Based on this finding, we engineered ΔppGpp S. Gallinarum to express constitutively a recombinant immunotoxin comprising TGFα and the Pseudomonas exotoxin A (PE38) using a constitutive exponential phase promoter, the ribosomal RNA promoter rrnB P1. The construct exerted anticancer effects on mice grafted with mouse colon (CT26) or breast (4T1) tumor cells without any notable adverse effects, suggesting that constitutive expression of cytotoxic anticancer protein from rrnB P1 occurred only in tumor tissue.
- 25 May 2022
- Published by The Microbiological Society of Korea in Journal of Microbiology
- Vol. 60  (8) , 859-866
Eradication of drug-resistant Acinetobacter baumannii by cell-penetrating peptide fused endolysin
Antimicrobial agents targeting peptidoglycan have shown successful results in eliminating bacteria with high selective toxicity. Bacteriophage encoded endolysin as an alternative antibiotics is a peptidoglycan degrading enzyme with a low rate of resistance. Here, the engineered endolysin was developed to defeat multiple drug-resistant (MDR) Acinetobacter baumannii. First, putative endolysin PA90 was predicted by genome analysis of isolated Pseudomonas phage PBPA. The His-tagged PA90 was purified from BL21(DE3) pLysS and tested for the enzymatic activity using Gram-negative pathogens known for having a high antibiotic resistance rate including A. baumannii. Since the measured activity of PA90 was low, probably due to the outer membrane, cell-penetrating peptide (CPP) DS4.3 was introduced at the N-terminus of PA90 to aid access to its substrate. This engineered endolysin, DS-PA90, completely killed A. baumannii at 0.25 µM, at which concentration PA90 could only eliminate less than one log in CFU/ml. Additionally, DS-PA90 has tolerance to NaCl, where the ∼50% of activity could be maintained in the presence of 150 mM NaCl, and stable activity was also observed with changes in pH or temperature. Even MDR A. baumannii strains were highly susceptible to DS-PA90 treatment: five out of nine strains were entirely killed and four strains were reduced by 3–4 log in CFU/ml. Consequently, DS-PA90 could protect waxworm from A. baumannii-induced death by ∼70% for ATCC 17978 or ∼44% for MDR strain 1656-2 infection. Collectively, our data suggest that CPP-fused endolysin can be an effective antibacterial agent against Gram-negative pathogens regardless of antibiotics resistance mechanisms.
- 25 May 2022
- Published by The Microbiological Society of Korea in Journal of Microbiology
- Vol. 60  (8) , 859-866
Eradication of drug-resistant Acinetobacter baumannii by cell-penetrating peptide fused endolysin
Antimicrobial agents targeting peptidoglycan have shown successful results in eliminating bacteria with high selective toxicity. Bacteriophage encoded endolysin as an alternative antibiotics is a peptidoglycan degrading enzyme with a low rate of resistance. Here, the engineered endolysin was developed to defeat multiple drug-resistant (MDR) Acinetobacter baumannii. First, putative endolysin PA90 was predicted by genome analysis of isolated Pseudomonas phage PBPA. The His-tagged PA90 was purified from BL21(DE3) pLysS and tested for the enzymatic activity using Gram-negative pathogens known for having a high antibiotic resistance rate including A. baumannii. Since the measured activity of PA90 was low, probably due to the outer membrane, cell-penetrating peptide (CPP) DS4.3 was introduced at the N-terminus of PA90 to aid access to its substrate. This engineered endolysin, DS-PA90, completely killed A. baumannii at 0.25 µM, at which concentration PA90 could only eliminate less than one log in CFU/ml. Additionally, DS-PA90 has tolerance to NaCl, where the ∼50% of activity could be maintained in the presence of 150 mM NaCl, and stable activity was also observed with changes in pH or temperature. Even MDR A. baumannii strains were highly susceptible to DS-PA90 treatment: five out of nine strains were entirely killed and four strains were reduced by 3–4 log in CFU/ml. Consequently, DS-PA90 could protect waxworm from A. baumannii-induced death by ∼70% for ATCC 17978 or ∼44% for MDR strain 1656-2 infection. Collectively, our data suggest that CPP-fused endolysin can be an effective antibacterial agent against Gram-negative pathogens regardless of antibiotics resistance mechanisms.
- Open Access
- 20 May 2022
- Published by Korean Society for Microbiology and Biotechnology in Journal of Microbiology and Biotechnology
- Vol. 32  (6) , 816-823
Bactericidal Effect of Cecropin A Fused Endolysin on Drug-Resistant Gram-Negative Pathogens
Jeonghyun Lim, Juyeon Hong, Yongwon Jung, Jaewon Ha, Hwan Kim, Heejoon Myung, and Miryoung Song. J. Microbiol. Biotechnol. 2022;32:816-23. https://doi.org/10.4014/jmb.2205.05009
- 20 May 2022
- Published by Korean Society for Microbiology and Biotechnology in Journal of Microbiology and Biotechnology
- Vol. 32  (6) , 816-823
Open AccessBactericidal Effect of Cecropin A Fused Endolysin on Drug-Resistant Gram-Negative Pathogens
Jeonghyun Lim, Juyeon Hong, Yongwon Jung, Jaewon Ha, Hwan Kim, Heejoon Myung, and Miryoung Song. J. Microbiol. Biotechnol. 2022;32:816-23. https://doi.org/10.4014/jmb.2205.05009